Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2017, Article ID 2979486, 3 pages
https://doi.org/10.1155/2017/2979486
Case Report

Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus

Mayo Clinic, Rochester, MN, USA

Correspondence should be addressed to Kara A. Bjur; ude.oyam@arak.rujb

Received 22 November 2016; Accepted 12 February 2017; Published 26 February 2017

Academic Editor: John W. Berkenbosch

Copyright © 2017 Kara A. Bjur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. R. Fowles, M. I. Banton, and L. H. Pottenger, “A toxicological review of the propylene glycols,” Critical Reviews in Toxicology, vol. 43, no. 4, pp. 363–390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Zar, C. Graeber, and M. A. Perazella, “Recognition, treatment, and prevention of propylene glycol toxicity,” Seminars in Dialysis, vol. 20, no. 3, pp. 217–219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Y. Lim, R. L. Poole, and N. M. Pageler, “Propylene glycol toxicity in children,” The Journal of Pediatric Pharmacology and Therapeutics, vol. 19, no. 4, pp. 277–282, 2014. View at Google Scholar
  4. K. A. Tuohy, W. J. Nicholson, and F. Schiffman, “Agitation by sedation,” Lancet, vol. 361, no. 9354, p. 308, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Arulanantham and M. Genel, “Central nervous system toxicity associated with ingestion of propylene glycol,” Journal of Pediatrics, vol. 93, no. 3, pp. 515–516, 1978. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Shehab, C. L. Lewis, D. D. Streetman, and S. M. Donn, “Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates,” Pediatric Critical Care Medicine, vol. 10, no. 2, pp. 256–259, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Barnes, C. Gerst, J. R. Smith, A. R. Terrell, and M. E. Mullins, “Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation,” Pharmacotherapy, vol. 26, no. 1, pp. 23–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Nelsen, C. E. Haas, B. Habtemariam et al., “A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients,” Journal of Intensive Care Medicine, vol. 23, no. 3, pp. 184–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. G. Parker, G. L. Fraser, D. M. Watson, and R. R. Riker, “Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy,” Intensive Care Medicine, vol. 28, no. 1, pp. 81–84, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Hansen, R. Lange, and S. Gupta, “Development and evaluation of a guideline for monitoring propylene glycol toxicity in pediatric intensive care unit patients receiving continuous infusion lorazepam,” The Journal of Pediatric Pharmacology and Therapeutics, vol. 20, no. 5, pp. 367–372, 2015. View at Google Scholar
  11. K. M. Morshed, S. K. Jain, and K. E. Mcmartin, “Acute toxicity of propylene glycol: an assessment using cultured proximal tubule cells of human origin,” Toxicological Sciences, vol. 23, no. 1, pp. 38–43, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Morshed, S. K. Jain, and K. E. McMartin, “Propylene glycol-mediated cell injury in a primary culture of human proximal tubule cells,” Toxicological Sciences, vol. 46, no. 2, pp. 410–417, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. P. D. Yorgin, A. A. Theodorou, A. Al-Uzri, K. Davenport, L. V. Boyer-Hassen, and M. I. Johnson, “Propylene glycol-induced proximal renal tubular cell injury,” American Journal of Kidney Diseases, vol. 30, no. 1, pp. 134–139, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. European Medicine Agency, “Guidelines: excipients in the label and package leaflet of medicinal products for human use,” Revision 1, July 2003, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003412.pdf.
  15. European Medicine Agency, “Questions & answers on propylene glycol and esters in the context of the revision of the guideline on ‘excipients in the label and package leaflet of medicinal products for human use’ (CPMP/463/00 Rev. 1),” Tech. Rep. EMA/CHMP/704195/2013, 2014. View at Google Scholar